Question: is acalabrutinib fda approved for cll?
Answer: Project Orbis: FDA approves acalabrutinib for CLL and SLL. On November 21, 2019, the Food and Drug Administration approved acalabrutinib (CALQUENCE, AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).